In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome
More about Open Access at the CrickAuthors list
Gaëlle Naert Valentine Ferré Emeline Keller Amy Slender Dorota Gibbins Elizabeth MC Fisher Victor Tybulewicz Tangui MauriceAbstract
The prevalence of Alzheimer's disease is increased in people with Down syndrome. The pathology appears much earlier than in the general population, suggesting a predisposition to develop Alzheimer's disease. Down syndrome results from trisomy of human chromosome 21, leading to overexpression of possible Alzheimer's disease candidate genes, such as amyloid precursor protein gene. To better understand how the Down syndrome context results in increased vulnerability to Alzheimer's disease, we analysed amyloid-β [25-35] peptide toxicity in the Tc1 mouse model of Down syndrome, in which ~75% of protein coding genes are functionally trisomic but, importantly, not amyloid precursor protein.
Journal details
Journal Journal of Psychopharmacology
Volume 32
Issue number 2
Pages 174-190
Available online
Publication date
Full text links
Publisher website (DOI) 10.1177/0269881117743484
Figshare View on figshare
Europe PubMed Central 29215943
Pubmed 29215943
Keywords
Related topics
Type of publication